main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Brightcove Cards Listing

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Prostate Cancer6m 59s

    Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

    3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
    nmcrpc metastasis free survival spartan prosper & aramis clinical trial
  • Breast Cancer36m 42s

    Clinical Challenges in Management of Hormone Receptor Positive -Her 2 Negative Advanced Breast Cancer (ABC)

    The landscape of HR+ve/HER2-negative metastatic breast cancer (MBC) has evolved significantly with the introduction of newer treatment options such as CDK4/6 inhibitors, PI3K inhibitors, and selective estrogen receptor down regulators.
    management of hr+/her2- breast cancer cdk4/6 inhibitors serds pi3k inhibitors biomarkers
  • Multiple Myeloma10m 40s

    Recommendations -Management of Myeloma Related Renal Impairment

    Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.
    myeloma renal impairment lancet guidelines
  • Breast Cancer3m 56s

    Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission

    There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
    her2 positive mbc prolonged remission trastuzumab duration
  • Multiple Myeloma9m 20s

    Integrating Pomalidomide Based Regimens in Multiple Myeloma

    Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
    pomalidomide-dexamethasone rrmm management progression-free survival combination therapies
  • Myelodysplastic Syndromes8m 45s

    Current Challenges in MDS Diagnosis and Consequences

    Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
    non invasive mds diagnosis web based mds diagnosis tools
  • Multiple Myeloma7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Myelodysplastic Syndromes5m 42s

    Integrating Molecular Prognositic Systems in Management of MDS

    Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.
    molecular prognostic systems ipss-m prediction of disease progression
  • Prostate Cancer45m 55s

    Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)

    Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)
    metastatic hormone-sensitive prostate cancer (mhspc) androgen deprivation therapy (adt) chemotherapy docetaxel improved patient survival rates
  • Prostate Cancer11m 38s

    Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer

    PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
    treatment intensification mhspc triplet therapy peace-1 clinical trial
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback